Spectral Medical (TSE:EDT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Spectral Medical Inc. reported robust enrollment in the Tigris trial for its Polymyxin B Hemoperfusion treatment for septic shock, with completion expected by the end of 2024. Additionally, the company anticipates a positive impact from the Vantive-Carlyle Group transaction on the commercialization of its products.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
